Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ARDXthis companyArdelyx, Inc.	$2.96	-22.42×	8.42×	3.45×	-53.09×	-5941.7%	89.5%	-10.1%	-15.1%	-36.9%	-9.9%	-3.1%	1.27×	-4.92×	-1.44×	4.31×	0.0%	2	-0.11	1	D+
AKBAAkebia Therapeutics, Inc.	$0.49	-77.4×	12.7×	1.75×	20.5×	-604.2%	83.3%	9.9%	-2.3%	-16.4%	9.3%	16.4%	6.63×	1.45×	0.97×	1.13×	0.0%	3	-5.78	1	D+
DMACDiaMedica Therapeutics Inc.	$9.76	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
MAZEMaze Therapeutics, Inc.	$34.30	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
XERSXeris Biopharma Holdings, Inc.	$15.35	2,242.86×	92×	4.32×	93.32×	-804.3%	81.7%	8.5%	0.2%	4.0%	8.9%	2.2%	2.76×	-5.77×	0.86×	2.19×	0.0%	5	1.35	2	C
Peer median	—	-12.48×	9.68×	0.88×	4.77×	-350.5%	40.8%	4.3%	0.0%	-26.7%	-14.4%	-2.1%	1.41×	0.88×	0.43×	7×	0.0%	3	6.45	2	—